$EXEL
EXELIXIS, INC. Stock $exel

$exel Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-K Financial Statement

#000162828021001852 Filed on February 11, 2021

Income Statement

Concept	2021 Q1	2021	2020 Q4
Revenue	$270.1M	$987.5M	$231.1M
YoY Change	19.02%	2.04%	-3.83%
Cost Of Revenue	$13.20M	$36.27M	$8.725M
YoY Change	41.94%	9.59%	-16.9%
Gross Profit	$191.3M	$951.3M	$159.9M
YoY Change	-12.08%	1.77%	-30.43%
Gross Profit Margin	70.84%	96.33%	69.18%
Selling, General & Admin	$102.4M	$293.4M	$88.19M
YoY Change	62.8%	28.53%	52.04%
% of Gross Profit	53.52%	30.84%	55.16%
Research & Development	$159.3M	$547.9M	$176.8M
YoY Change	56.33%	62.58%	87.25%
% of Gross Profit	83.27%	57.59%	110.57%
Depreciation & Amortization	$3.200M	$9.141M	$2.400M
YoY Change	45.45%	9.5%	9.09%
% of Gross Profit	1.67%	0.96%	1.5%
Operating Expenses	$261.6M	$841.2M	$264.9M
YoY Change	58.74%	40.6%	73.74%
Operating Profit	$24.30M	$110.1M	-$42.58M
YoY Change	-53.98%	-70.21%	-155.08%
Interest Expense	$2.700M	$7.672M	$3.500M
YoY Change	-62.5%		-54.55%
% of Operating Profit	11.11%	6.97%
Other Income/Expense, Net	-$100.0K	$912.0K	$565.0K
YoY Change		-96.82%
Pretax Income	-$2.000M	$130.8M	-$38.02M
YoY Change	-103.33%	-67.14%	-144.73%
Income Tax	-$3.600M	$19.06M	-$5.981M
% Of Pretax Income		14.56%
Net Earnings	$28.39M	$111.8M	-$32.04M
YoY Change	-41.59%	-65.18%	-146.64%
Net Earnings / Revenue	10.51%	11.32%	-13.86%
Basic Earnings Per Share	$0.09	$0.36	-$0.10
Diluted Earnings Per Share	$0.09	$0.35	-$0.10
COMMON SHARES
Basic Shares Outstanding	312.0M shares	308.3M shares	309.1M shares
Diluted Shares Outstanding		318.0M shares	309.1M shares

Balance Sheet

Concept	2021 Q1	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.186B	$1.467B	$1.207B
YoY Change	24.21%	21.6%	41.57%
Cash & Equivalents	$319.2M	$647.2M	$334.0M
Short-Term Investments	$815.3M	$819.9M	$887.3M
Other Short-Term Assets	$46.30M	$57.53M	$57.00M
YoY Change	55.37%	0.93%	111.11%
Inventory	$20.97M	$27.49M	$19.32M
Prepaid Expenses
Receivables	$177.7M	$282.7M	$160.9M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.445B	$1.835B	$1.408B
YoY Change	42.94%	26.94%	39.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$67.38M	$149.2M	$56.39M
YoY Change	37.82%	35.1%	15.31%
Goodwill	$63.68M		$63.68M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$279.1M	$371.1M	$332.3M
YoY Change	-42.38%	11.68%	-38.05%
Other Assets	$73.41M	$195.9M	$69.41M
YoY Change	38.13%	5.54%	-69.22%
Total Long-Term Assets	$691.9M	$781.5M	$703.2M
YoY Change	-20.87%	12.95%	-19.58%
TOTAL ASSETS
Total Short-Term Assets	$1.445B	$1.835B	$1.408B
Total Long-Term Assets	$691.9M	$781.5M	$703.2M
Total Assets	$2.137B	$2.616B	$2.111B
YoY Change	13.35%	22.41%	11.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$23.63M	$24.26M	$47.93M
YoY Change	104.06%	2.79%	313.16%
Accrued Expenses	$111.2M	$231.4M	$115.9M
YoY Change	58.18%	99.66%	27.78%
Deferred Revenue	$1.790M		$1.300M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$204.7M	$337.6M	$201.3M
YoY Change	43.37%	64.92%	41.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$721.0K	$68.03M	$721.0K
YoY Change	-69.28%	26.93%	-98.74%
Total Long-Term Liabilities	$721.0K	$68.03M	$721.0K
YoY Change	-69.28%	26.93%	-98.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$204.7M	$337.6M	$201.3M
Total Long-Term Liabilities	$721.0K	$68.03M	$721.0K
Total Liabilities	$258.2M	$405.6M	$259.0M
YoY Change	29.3%	57.1%	29.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$447.6M		-$476.0M
YoY Change	-19.98%
Common Stock	$312.0K		$309.0K
YoY Change	2.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.879B	$2.211B	$1.852B
YoY Change
Total Liabilities & Shareholders Equity	$2.137B	$2.616B	$2.111B
YoY Change	13.35%	22.41%	11.95%

Cashflow Statement

Concept	2021 Q1	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	$28.39M	$111.8M	-$32.04M
YoY Change	-41.59%	-65.18%	-146.64%
Depreciation, Depletion And Amortization	$3.200M	$9.141M	$2.400M
YoY Change	45.45%	9.5%	9.09%
Cash From Operating Activities	$39.50M	$209.0M	$33.30M
YoY Change	-29.59%	-60.34%	-78.94%
INVESTING ACTIVITIES
Capital Expenditures	-$13.60M	$30.35M	-$14.20M
YoY Change	353.33%	136.44%	97.22%
Acquisitions
YoY Change
Other Investing Activities	$75.80M	$21.34M	-$15.20M
YoY Change	112.92%	-121.15%	-87.63%
Cash From Investing Activities	$62.30M	-$131.2M	-$29.50M
YoY Change	91.1%	-77.66%	-77.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.700M	-$25.13M	-18.70M
YoY Change	-228.57%	-300.21%	523.33%
NET CHANGE
Cash From Operating Activities	39.50M	$209.0M	33.30M
Cash From Investing Activities	62.30M	-$131.2M	-29.50M
Cash From Financing Activities	-2.700M	-$25.13M	-18.70M
Net Change In Cash	99.10M	$52.64M	-14.90M
YoY Change	9.14%	-210.26%	-159.84%
FREE CASH FLOW
Cash From Operating Activities	$39.50M	$209.0M	$33.30M
Capital Expenditures	-$13.60M	$30.35M	-$14.20M
Free Cash Flow	$53.10M	$178.6M	$47.50M
YoY Change	-10.15%	-65.25%	-71.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000939767
CY2020Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2021Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:otherassetsnoncurrent
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:otherassetsnoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-01-01
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-01
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	000-30235
CY2021	dei	Entity Registrant Name EntityRegistrantName	EXELIXIS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3257395
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1851 Harbor Bay Parkway
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Alameda,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94502
CY2021	dei	City Area Code CityAreaCode	650
CY2021	dei	Local Phone Number LocalPhoneNumber	837-7000
CY2021	dei	Security12b Title Security12bTitle	Common Stock $.001 Par Value per Share
CY2021	dei	Trading Symbol TradingSymbol	EXEL
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Public Float EntityPublicFloat	6399562142	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	311989661	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	319217000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	266501000	USD
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	887319000	USD
CY2020Q1	us-gaap	Short Term Investments ShortTermInvestments	585742000	USD
CY2021Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	160875000	USD
CY2020Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	119073000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	20973000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	12886000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57011000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	26988000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	1445395000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	1011190000	USD
CY2021Q1	us-gaap	Long Term Investments LongTermInvestments	332306000	USD
CY2020Q1	us-gaap	Long Term Investments LongTermInvestments	536385000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	67384000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48892000	USD
CY2021Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	156711000	USD
CY2020Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	172374000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	63684000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	63684000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	71853000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	53145000	USD
CY2021Q1	us-gaap	Assets Assets	2137333000	USD
CY2020Q1	us-gaap	Assets Assets	1885670000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	23632000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11581000	USD
CY2021Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	51189000	USD
CY2020Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	37364000	USD
CY2021Q1	exel	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	52251000	USD
CY2020Q1	exel	Accrued Clinical Liabilities Current AccruedClinicalLiabilitiesCurrent	38777000	USD
CY2021Q1	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	20683000	USD
CY2020Q1	us-gaap	Customer Refund Liability Current CustomerRefundLiabilityCurrent	18719000	USD
CY2021Q1	exel	Accrued Collaboration Liability Current AccruedCollaborationLiabilityCurrent	12456000	USD
CY2020Q1	exel	Accrued Collaboration Liability Current AccruedCollaborationLiabilityCurrent	11856000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	44447000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24449000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	204658000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	142746000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3755000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6596000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	49086000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48011000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	721000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2347000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	258220000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	199700000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	311627000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	311627000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	304831000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	304831000	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	312000	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	305000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2321895000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2241947000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4476000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3069000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-447570000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-559351000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1879113000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1685970000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2137333000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1885670000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	987538000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	967775000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	853826000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	36272000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	33097000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	26348000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	547851000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	336964000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	182257000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	293355000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	228244000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	206366000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	877478000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	598305000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	414971000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	110060000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	369470000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	438855000	USD
CY2021	us-gaap	Interest Income Other InterestIncomeOther	19865000	USD
CY2020	us-gaap	Interest Income Other InterestIncomeOther	27959000	USD
CY2018	us-gaap	Interest Income Other InterestIncomeOther	12840000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	912000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	680000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	397000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	130837000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	398109000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	452092000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19056000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	77097000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-237978000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	111781000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	321012000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	690070000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.06
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.32
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.35
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.02
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.21
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	308271000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	302584000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	297892000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	318001000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	315009000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	312803000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	111781000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	321012000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	690070000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	394000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1049000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-156000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1407000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3770000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-354000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	113188000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	324782000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	689716000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	284961000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	690070000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-354000	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20985000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7574000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40626000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1287453000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	321012000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3770000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	27037000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9904000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56602000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1685970000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	111781000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	111781000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1407000	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	24903000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	50018000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	105070000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1879113000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	111781000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	321012000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	690070000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9141000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8348000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4915000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	105070000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	56602000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	40626000	USD
CY2021	exel	Noncash Lease Expense NoncashLeaseExpense	4830000	USD
CY2020	exel	Noncash Lease Expense NoncashLeaseExpense	2819000	USD
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	969399000	USD
CY2018	exel	Noncash Lease Expense NoncashLeaseExpense	2854000	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-15265000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-71002000	USD
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	244111000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3035000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-88000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1129000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42470000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-43716000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	85471000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	21897000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5731000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3181000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	25831000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5723000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8525000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1051000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-9301000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	271000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	51109000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	44124000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	17143000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	208982000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	526956000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	415720000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30345000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12834000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33297000	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	308000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1070269000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1182682000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	557832000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	608269000	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	292971000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-131215000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-587247000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-297850000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	24886000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	22499000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	17278000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	50018000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	9904000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7574000	USD
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-42000	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-13000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-25132000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12553000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9691000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	52635000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-47738000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	127561000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268137000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	315875000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188314000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	320772000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268137000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	315875000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4115000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7873000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10677000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4017000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	29562000	USD
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17180000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	842000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	26000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	802000	USD
CY2021	exel	Investments Purchases Incurred But Not Yet Paid InvestmentsPurchasesIncurredButNotYetPaid	1615000	USD
CY2020	exel	Investments Purchases Incurred But Not Yet Paid InvestmentsPurchasesIncurredButNotYetPaid	0	USD
CY2018	exel	Investments Purchases Incurred But Not Yet Paid InvestmentsPurchasesIncurredButNotYetPaid	0	USD
CY2021	exel	Accounts Receivable For Unsettled Investment Sales AccountsReceivableForUnsettledInvestmentSales	6180000	USD
CY2020	exel	Accounts Receivable For Unsettled Investment Sales AccountsReceivableForUnsettledInvestmentSales	0	USD
CY2018	exel	Accounts Receivable For Unsettled Investment Sales AccountsReceivableForUnsettledInvestmentSales	0	USD
CY2021	us-gaap	Fiscal Period FiscalPeriod	We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31st. Fiscal year 2020, which was a 52-week fiscal year, ended on January 1, 2021, fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal years ended January 1, 2021, January 3, 2020 and December 28, 2018 are indicated as being as of and for the years ended December 31, 2020, 2019 and 2018, respectively.
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received the Preliminary Calculation of our Branded Prescription Drug Fee for 2020, and in August 2020, the Final Calculation of our Branded Prescription Drug Fee for 2020 from the Internal Revenue Service for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. Accordingly, we recorded an adjustment to increase selling, general and administrative expenses for these fees by $5.1 million during the fiscal year ended December 31, 2020. This adjustment resulted in a $0.02 decrease in basic and diluted </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings per share for the fiscal year ended December 31, 2020.</span></div>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	exel	Sales Revenue Percent Discount For Prompt Payment SalesRevenuePercentDiscountForPromptPayment	0.02
CY2021	exel	Sales Revenue Discount Expectedtobe Earned Percent SalesRevenueDiscountExpectedtobeEarnedPercent	1
CY2021	exel	Medicare Part D Funding Mandate MedicarePartDFundingMandate	0.70
CY2021	us-gaap	Advertising Expense AdvertisingExpense	25100000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	17900000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	14800000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	900000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	987538000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	967775000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	853826000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	987538000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	967775000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	853826000	USD
CY2018Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	17276000	USD
CY2020	exel	Valuation Allowances And Reserves Additions For Sales In Current Period ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod	193791000	USD
CY2020	exel	Valuation Allowances And Reserves Additions For Sales In Prior Period ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod	3880000	USD
CY2020	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	188714000	USD
CY2020Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	26233000	USD
CY2021	exel	Valuation Allowances And Reserves Additions For Sales In Current Period ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod	220748000	USD
CY2021	exel	Valuation Allowances And Reserves Additions For Sales In Prior Period ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod	293000	USD
CY2021	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	216738000	USD
CY2021Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	30536000	USD
CY2021Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2020Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1062000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1790000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3755000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6596000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5545000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6596000	USD
CY2021	exel	Contract With Customer Liability Including New Contract Revenue Recognized ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized	9200000	USD
CY2020	exel	Contract With Customer Liability Including New Contract Revenue Recognized ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized	6500000	USD
CY2018	exel	Contract With Customer Liability Including New Contract Revenue Recognized ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized	8700000	USD
CY2021	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	169700000	USD
CY2020	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	161200000	USD
CY2018	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	198100000	USD
CY2021Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	86100000	USD
CY2021Q1	exel	Milestone Payments Earned To Date MilestonePaymentsEarnedToDate	350000000.0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1355901000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	319217000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	266501000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1555000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	320772000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268137000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1349982000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5931000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12000	USD
CY2020Q1	us-gaap	Inventory Gross InventoryGross	16523000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2700000	USD
CY2021Q1	exel	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	1532923000	USD
CY2021Q1	exel	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5931000	USD
CY2021Q1	exel	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12000	USD
CY2021Q1	exel	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities	1538842000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1308351000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4121000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1312464000	USD
CY2020Q1	exel	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	1384510000	USD
CY2020Q1	exel	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4126000	USD
CY2020Q1	exel	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	USD
CY2020Q1	exel	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities	1388628000	USD
CY2021Q1	us-gaap	Interest Receivable InterestReceivable	4500000	USD
CY2020Q1	us-gaap	Interest Receivable InterestReceivable	6200000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	56299000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	12000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	17377000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	8000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	14	investment
CY2020Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	9	investment
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1034150000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	789913000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	321751000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	522551000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1355901000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1312464000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	7773000	USD
CY2020Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2709000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	20610000	USD
CY2020Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	9447000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7291000	USD
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4367000	USD
CY2021Q1	us-gaap	Inventory Gross InventoryGross	35674000	USD
CY2020Q1	us-gaap	Inventory Gross InventoryGross	16523000	USD
CY2021Q1	us-gaap	Inventory Gross InventoryGross	35674000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	1300000	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	1100000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	102068000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74452000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34684000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25560000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	67384000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48892000	USD
CY2021	us-gaap	Depreciation Depreciation	9100000	USD
CY2020	us-gaap	Depreciation Depreciation	8300000	USD
CY2018	us-gaap	Depreciation Depreciation	4900000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105070000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	56602000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40626000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105070000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	56602000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40626000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	17100727	shares
CY2021	exel	Share Based Compensation Arrangement By Share Based Payment Award Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward	1	shares
CY2021	exel	Share Based Compensation Arrangement By Share Based Payment Award Reduction In Share Reserve Due To Other Awards ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards	1.5	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	21000000	shares
CY2020Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	26792000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20443000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.91
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1637000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.89
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5633000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.77
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	318000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	20.12
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16129000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.72
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y1M6D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	131729000000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12656000	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.47
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y6M
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	128740000000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	6700000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4600000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3600000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3791000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6095000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6133000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3791000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6095000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6133000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	14886000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	71580000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-238675000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	379000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-578000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5436000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15265000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	71002000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-244111000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19056000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	77097000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-237978000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	27476000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	83603000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	94939000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2232000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1148000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	4690000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5525000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3208000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-315394000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	11356000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	8299000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	18308000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-20399000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-9177000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5998000	USD
CY2021	exel	Effective Income Tax Rate Reconciliation Nondeductible Expense Deferred Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation	18067000	USD
CY2020	exel	Effective Income Tax Rate Reconciliation Nondeductible Expense Deferred Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation	4228000	USD
CY2018	exel	Effective Income Tax Rate Reconciliation Nondeductible Expense Deferred Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDeferredCompensation	1111000	USD
CY2021	exel	Effective Income Tax Rate Reconciliation Branded Prescription Drug Fee EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee	2537000	USD
CY2020	exel	Effective Income Tax Rate Reconciliation Branded Prescription Drug Fee EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee	1099000	USD
CY2018	exel	Effective Income Tax Rate Reconciliation Branded Prescription Drug Fee EffectiveIncomeTaxRateReconciliationBrandedPrescriptionDrugFee	371000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-562000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1287000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	611000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19056000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	77097000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-237978000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37454000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	65131000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	126625000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	110037000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	18414000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	76060000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79342000	USD
CY2021Q1	exel	Deferred Tax Assets Amortization Of Deferred Stock Compensation Non Qualified DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified	19818000	USD
CY2020Q1	exel	Deferred Tax Assets Amortization Of Deferred Stock Compensation Non Qualified DeferredTaxAssetsAmortizationOfDeferredStockCompensationNonQualified	14966000	USD
CY2021Q1	exel	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	11908000	USD
CY2020Q1	exel	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	11211000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	12207000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	8248000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7637000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	6547000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2020Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	345000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	234063000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	243277000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67185000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61659000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	166878000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	181618000	USD
CY2021Q1	exel	Deferred Tax Liabilities Lease Right Of Use Assets DeferredTaxLiabilitiesLeaseRightOfUseAssets	9510000	USD
CY2020Q1	exel	Deferred Tax Liabilities Lease Right Of Use Assets DeferredTaxLiabilitiesLeaseRightOfUseAssets	9244000	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	657000	USD
CY2020Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2021Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	10167000	USD
CY2020Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9244000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	156711000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	172374000	USD
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67200000	USD
CY2020Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61700000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5500000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3500000	USD
CY2020Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79078000	USD
CY2021	exel	Unrecognized Tax Benefits Increase Decrease Resultingfrom Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions	591000	USD
CY2020	exel	Unrecognized Tax Benefits Increase Decrease Resultingfrom Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions	589000	USD
CY2018	exel	Unrecognized Tax Benefits Increase Decrease Resultingfrom Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromPriorPeriodTaxPositions	-4254000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3305000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2429000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1083000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2033000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	111000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	80941000	USD
CY2020Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	79078000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	76060000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	80900000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	50100000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	111781000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	321012000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	690070000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	308271000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	302584000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	297892000	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9730000	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12425000	shares
CY2018	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	14911000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	318001000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	315009000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	312803000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	226915000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	259479000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.06
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.32
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.35
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.02
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.21
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43010000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41835000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3025000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2728000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	231092000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	270052000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	184591000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	169509000	USD
CY2020Q4	us-gaap	Gross Profit GrossProfit	159862000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	191316000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	49086000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48011000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	52111000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	50739000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	4825000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2844000	USD
CY2018	us-gaap	Operating Lease Cost OperatingLeaseCost	4189000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	2830000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	1024000	USD
CY2018	us-gaap	Variable Lease Cost VariableLeaseCost	1661000	USD
CY2021	us-gaap	Lease Cost LeaseCost	7655000	USD
CY2020	us-gaap	Lease Cost LeaseCost	3868000	USD
CY2018	us-gaap	Lease Cost LeaseCost	5850000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	4600000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	52809000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	75534000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-42580000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4834000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4994000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5332000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5600000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5773000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	37290000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	63823000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9970000	USD
CY2021Q1	exel	Lessee Operating Lease Liability Tenant Improvement Reimbursements LesseeOperatingLeaseLiabilityTenantImprovementReimbursements	1742000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	52111000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.031
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y9M18D
CY2021Q1	us-gaap	Tenant Improvements TenantImprovements	2800000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	24297000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	48612000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	66821000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-32040000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	28388000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
CY2020Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	215487000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	240275000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	271703000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	240310000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	172080000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	186136000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	184231000	USD
	us-gaap	Gross Profit GrossProfit	184406000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	84559000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	91989000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	115606000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	77316000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	75775000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	79042000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	97452000	USD
	us-gaap	Net Income Loss NetIncomeLoss	68743000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.25
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.22
CY2020Q2	exel	Milestone Payments Earned MilestonePaymentsEarned	100000	USD
CY2020Q3	exel	Milestone Payments Earned MilestonePaymentsEarned	43500000	USD
CY2020Q4	exel	Milestone Payments Earned MilestonePaymentsEarned	13500000	USD
CY2021Q1	exel	Milestone Payments Earned MilestonePaymentsEarned	29400000	USD
CY2019Q1	exel	Milestone Payments Earned MilestonePaymentsEarned	10000000.0	USD
CY2019Q2	exel	Milestone Payments Earned MilestonePaymentsEarned	20400000	USD
CY2019Q3	exel	Milestone Payments Earned MilestonePaymentsEarned	50600000	USD
	exel	Milestone Payments Earned MilestonePaymentsEarned	15100000	USD

Files In Submission

Name	View Source	Status
0001628280-21-001852-index-headers.html	Edgar Link	pending
0001628280-21-001852-index.html	Edgar Link	pending
0001628280-21-001852.txt	Edgar Link	pending
0001628280-21-001852-xbrl.zip	Edgar Link	pending
exel-20210101.htm	Edgar Link	pending
exel-20210101.xsd	Edgar Link	pending
exel-20210101_cal.xml	Edgar Link	unprocessable
exel-20210101_def.xml	Edgar Link	unprocessable
exel-20210101_g1.jpg	Edgar Link	pending
exel-20210101_g2.jpg	Edgar Link	pending
exel-20210101_htm.xml	Edgar Link	completed
exel-20210101_lab.xml	Edgar Link	unprocessable
exel-20210101_pre.xml	Edgar Link	unprocessable
exel20201231exhibit1011.htm	Edgar Link	pending
exel20201231exhibit1032.htm	Edgar Link	pending
exel20201231exhibit211.htm	Edgar Link	pending
exel20201231exhibit231.htm	Edgar Link	pending
exel20201231exhibit311.htm	Edgar Link	pending
exel20201231exhibit312.htm	Edgar Link	pending
exel20201231exhibit321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_11.jpg	Edgar Link	pending
image_21.jpg	Edgar Link	pending
image_31.jpg	Edgar Link	pending
image_41.jpg	Edgar Link	pending
image_51.jpg	Edgar Link	pending
image_61.jpg	Edgar Link	pending
image_71.jpg	Edgar Link	pending
image_81.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EXEL
EXELIXIS, INC. Stock $exel

2021 Q1 Form 10-K Financial Statement

#000162828021001852 Filed on February 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL EXELIXIS, INC. Stock $exel

2021 Q1 Form 10-K Financial Statement

#000162828021001852 Filed on February 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL
EXELIXIS, INC. Stock $exel